Capital City Trust Co. FL reduced its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 12.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,360 shares of the medical research company’s stock after selling 2,406 shares during the period. Thermo Fisher Scientific makes up 1.2% of Capital City Trust Co. FL’s holdings, making the stock its 20th largest position. Capital City Trust Co. FL’s holdings in Thermo Fisher Scientific were worth $3,029,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock valued at $3,989,193,000 after buying an additional 695,079 shares in the last quarter. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after buying an additional 22,165,530 shares in the last quarter. State Street Corp raised its stake in Thermo Fisher Scientific by 1.0% in the first quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock valued at $2,470,802,000 after buying an additional 164,367 shares in the last quarter. Wellington Management Group LLP raised its stake in Thermo Fisher Scientific by 5.6% in the first quarter. Wellington Management Group LLP now owns 7,512,152 shares of the medical research company’s stock valued at $1,153,867,000 after buying an additional 398,622 shares in the last quarter. Finally, Morgan Stanley raised its stake in Thermo Fisher Scientific by 7.6% in the first quarter. Morgan Stanley now owns 4,664,882 shares of the medical research company’s stock valued at $716,526,000 after buying an additional 327,826 shares in the last quarter. Institutional investors own 83.52% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (TMO) opened at 186.00 on Friday. The firm has a 50 day moving average price of $177.39 and a 200-day moving average price of $168.43. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $188.76. The firm has a market capitalization of $72.56 billion, a P/E ratio of 32.40 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. During the same period in the prior year, the business earned $2.03 earnings per share. The business’s revenue was up 10.2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, September 14th. This represents a $0.60 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/02/capital-city-trust-co-fl-lowers-stake-in-thermo-fisher-scientific-inc-tmo.html.

Several equities research analysts have commented on the company. Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Saturday, June 10th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen and Company restated a “buy” rating and issued a $200.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday. Wells Fargo & Company restated an “outperform” rating and issued a $200.00 price objective (up previously from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $175.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, May 17th. One analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $189.50.

In related news, Director C Martin Harris sold 360 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the transaction, the director now directly owns 5,312 shares in the company, valued at $961,312.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the transaction, the director now owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The disclosure for this sale can be found here. Insiders sold 21,344 shares of company stock valued at $3,741,071 over the last quarter. Insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.